Alterity Therapeutics Limited, a development stage enterprise, has announced the issuance of unquoted equity securities under an employee incentive scheme. The announcement, dated June 28, 2024, detailed the issue of three new classes of options not intended to be quoted on the ASX. These options, with expiry dates ranging from March 13 to March 21, 2029, and exercise prices between AUD 0.004 and USD 0.003, were issued on June 27, 2024. A total of 209 million options were distributed across the three classes, with the largest single issuance of 120 million options granted to David Stamler, a key management personnel. The options, upon exercise, will convert into ordinary fully paid shares of Alterity Therapeutics. The company confirmed that the securities were issued under an exception in Listing Rule 7.2, negating the need for security holder approval.

Alterity Therapeutics Limited, a development stage enterprise, has announced the issuance of unquoted equity securities under an employee incentive scheme. The announcement, dated June 28, 2024, detailed the issue of three new classes of options not intended to be quoted on the ASX. These options, with expiry dates ranging from March 13 to March 21, 2029, and exercise prices between AUD 0.004 and USD 0.003, were issued on June 27, 2024. A total of 209 million options were distributed across the three classes, with the largest single issuance of 120 million options granted to David Stamler, a key management personnel. The options, upon exercise, will convert into ordinary fully paid shares of Alterity Therapeutics. The company confirmed that the securities were issued under an exception in Listing Rule 7.2, negating the need for security holder approval.